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Abstract
Background: Results from studies assessing the association between anticholinergic use and falls are mixed, and
prior studies are limited in their ability to control for important potential confounders. Thus, we sought to examine
the association between anticholinergic medication use, including over-the-counter medications, and recurrent falls
in community-dwelling older women.
Methods: We analyzed data from a prospective cohort study of women aged 65 to 79 years from the Women’s
Health Initiative Observational Study and Clinical Trials. Women were recruited between 1993 and 1998, and
analyses included 61,451 women with complete information. Medications with moderate or strong anticholinergic
effects were ascertained directly from drug containers during face-to-face interviews. The main outcome measure
was recurrent falls (≥2 falls in previous year), which was determined from self-report within 1.5 years subsequent to
the medication assessment.
Results: At baseline, 11.3 % were using an anticholinergic medication, of which antihistamines (commonly available
over-the-counter) were the most common medication class (received by 45.2 % of individuals on anticholinergic
medication). Using multivariable GEE models and controlling for potential confounders, the adjusted odds ratio for
anticholinergic medication use was 1.51 (95 % CI, 1.43–1.60) for recurrent falls. Participants using multiple
anticholinergic medications had a 100 % increase in likelihood of recurrent falls (adjusted odds ratio 2.00, 95 % CI
1.73–2.32). Results were robust to sensitivity analysis.
Conclusions: Anticholinergic medication use was associated with increased risk for recurrent falls. Our findings
reinforce judicious use of anticholinergic medications in older women. Public health efforts should emphasize
educating older women regarding the risk of using over-the-counter anticholinergics, such as first-generation
antihistamines.
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Background
Falls in older adults are significant public health con-
cerns [1]. Approximately one-third of community-
dwelling older adults fall at least once each year, of
whom nearly 50 % have recurrent falls [2, 3]. Recurrent
falls (as opposed to single falls) may be more clinically
important as they may increase the risk of physician
visits, functional status decline, nursing home admission,
and death [2]. Moreover, the etiology of falls is multifac-
torial, including both extrinsic (e.g., environmental) and
intrinsic (e.g., muscle weakness) risk factors. Import-
antly, identifying potentially modifiable risk factors for
falls is vital in order to reduce the risk of falls in older
adults.
Several medication classes, many of which have central
nervous system effects, have been associated with in-
creased risk for falls and fractures [4]. Medications with
anticholinergic effects have many adverse effects that
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could contribute to falls risk, including blurred vision,
sedation, and cognitive impairment [5, 6]. The preva-
lence of anticholinergic medication use is common
with 13–25 % of community-dwelling older adults
taking at least one agent [7–9]. Highly anticholinergic
medications are considered as potentially inappropri-
ate for use in older adults [10]. Moreover, nonphar-
macological strategies or alternative medications
without anticholinergic effects are often available to
treat these specific conditions (e.g., sleep disturbances,
urinary incontinence); therefore, reducing anticholin-
ergic polypharmacy is feasible.
The prospective cohort studies assessing the associ-
ation between anticholinergic use and falls in commu-
nity residing older adults have found mixed results [11–
14]. One possible explanation for these mixed results
may be due to differences in study designs and in the
measurement of falls (e.g., self-reported vs. claims meas-
urement, single vs. recurrent falls). Moreover, anticholin-
ergic use has been reported to be associated with falls in
high-risk populations of psychiatric inpatients, patients
after traumatic brain injury, and residential care facility
residents [15–17]. However, much of the research on
anticholinergic use and fall risk among older adults has
been limited by use of a cross-sectional design [18] and
use of highly select samples that may not be representa-
tive to the majority of older adults [15–17]. In addition,
most prior research on this topic has been conducted in
non-US populations. This is important because in the
US over-the-counter medication data are not available in
administrative pharmacy claims, resulting in limited
prior literature taking this type of medication exposure
into account. Thus, additional studies are warranted in
large samples to understand potential risks of these
medications. The objective of this study was to examine
the association between anticholinergic medication use,
including over-the-counter medications, and recurrent
falls in community-dwelling women.
Methods
Study population
The Women’s Health Initiative (WHI) studies included
three Clinical Trials (CT) and an Observational Study
(OS) that enrolled participants between 1993 and 1998
from 40 clinical centers across the United States. Study
methods have been described in detail elsewhere [19].
This analysis included postmenopausal women aged 65–
79 years upon study entry; 43,612 women from the Ob-
servational Study and 24,427 from the Clinical Trials.
We excluded women without a falls assessment within
1.5 years of their baseline medication inventory (n =
4033) to ensure the timeliness of the falls relative to
medication use, leaving a total sample of 67,006. In-
formed consent was obtained, and all protocols were
approved by the respective institutional review boards at
participating institutions.
Outcome ascertainment: recurrent falls
Fall history was obtained by asking participants to report
the number of times they fell and landed on the floor or
ground in the past 12 months. Self-reported falls were
ascertained annually for women in the OS and every
6 months for women in the CT by use of standardized
questionnaires. We defined a participant as having re-
current falls if she reported falling two or more times
during the previous 12-month period [20, 21]. This
method of fall recall (in the previous 12 months) has
been shown to be highly specific (91–95 %) in compari-
son with that reported using more frequent assessments
[22]. All participants (n = 67,006) had a baseline falls his-
tory collected.
Anticholinergic medication use
Women were asked about current prescription and
over-the-counter medications that were taken in the past
2 weeks at the baseline and year 3 clinic visits. The
medication information was obtained directly from the
medication containers and entered into the WHI data-
base. Each medication was assigned a drug code using
Medispan software (First DataBank, Inc., San Bruno,
California). Women were also asked how long they had
used each medication. No information on dose was
collected.
We adapted the Anticholinergic Drug Scale and fo-
cused on medications with moderate to strong anti-
cholinergic activity (see Table 1) [23, 24]. This list was
updated by consensus process by study investigators
with expertise in pharmacology (co-authors H.W., S.G.,
R.C.) by using new information (serum anticholinergic
activity, receptor binding affinity) and reviewing add-
itional anticholinergic scales [25, 26].
Measurement of other covariates
Questionnaires were used to collect information on age,
race and ethnicity, history of falls, self-reported health,
smoking status, and physical activity from walking out-
side the home for more than 10 min without stopping
(minutes per week). Alcohol consumption was estimated
from the responses on the food-frequency questionnaire.
Body mass index was calculated from measured height
and weight (weight, kg/height, m2). Physical function
was measured from the 10-item Rand Physical Function
scale (>90 indicating higher function) [27].
Anticholinergics can be used for a variety of condi-
tions. Therefore, to control for potential confounding by
indication we measured self-reported of physician-
diagnosed medical conditions for which anticholinergics
may be used – urinary incontinence and Parkinson’s
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disease. Other medical conditions measured to address
potential confounding by indication included insomnia
and depressive symptoms. The 5-item WHI Insomnia
Rating Scale was used for perceived insomnia symptoms,
including sleep latency, sleep maintenance insomnia,
early morning awakening, and sleep quality [28]. For each
question, the score ranges from 0 to 4, and the summary
score ranges from 0 to 20, with higher scores indicate
greater insomnia. We classified the score for insomnia
into four categories (0–3, 4–6, 7–10, and ≥11) consistent
with a previous study [28]. The Centers for Epidemiologic
Studies-Depression 6-item questionnaire was used to as-
sess depressive symptoms (Burnham score >0.06) [29, 30].
In addition, diabetes was defined as presence of oral
hypoglycemic medication or insulin, and Alzheimer Dis-
ease was measured via self-report of physician-diagnosed
disease and/or use of an anti-dementia medication (i.e.,
acetylcholinesterase inhibitors or NMDA receptor antag-
onist). Arthritis was measured via self-report of a phys-
ician diagnosis. Baseline medication covariates included
non-anticholinergic antiepileptics and psychoactive med-
ications (benzodiazepine receptor agonists, antidepres-
sants, and antipsychotics). Self-reported moderate/severe
dizziness, back pain (moderate severe), and uncorrected
vision problems were also assessed.
Statistical analysis
We used appropriate descriptive statistics for
summarization and generalized estimating equations
(GEE) for eliciting the main findings, allowing for
multiple observations per participant. Odds ratios
and 95 % confidence intervals were estimated from
the GEE models that included baseline and year 3
medication exposure information, and recurrent falls
in the following year as the outcome. Covariate data
were from baseline. We included only women with-
out missing covariate data for the primary analysis
(N = 61,451). The primary analysis examined any use
of anticholinergics as the main independent variable
of interest and the risk of recurrent falls reported in
1.5 years subsequent to the assessment as the out-
come. Since the focus of the analysis was on falls
most proximal to medication use, only the most re-
cent fall assessment (within 1.5 years) was used.
Baseline and year 3 anticholinergic use was used to
define the exposure in the primary analyses. All
models were adjusted by age using 5-year age inter-
vals and study component (clinical trial vs. observa-
tional study). We examined three models: Model 1
was adjusted for linear age at screening, diet modifi-
cation (DM) trial, and Calcium/vitamin D (CaD) trial
randomization arms; Model 2 was adjusted as Model
1, with additional adjustment for race/ethnicity, body
mass index, poor vision, arthritis, treated diabetes,
low back pain, Alzheimer Disease and/or use of anti-
dementia medication, Parkinson’s Disease, urinary in-
continence, depression, insomnia, self-reported
health, alcohol intake, use of antiepileptics, and
number of psychoactive medications. Most prior
Table 1 Frequency of Anticholinergic Medications at Baseline
according to Therapeutic Class
Drug Class Medicationa N
Antihistamines
Diphenhydramine 5411
Chlorpheniramine 1408
Hydroxyzine 742
Doxylamine 219
Clemastine 153
Dexchlorpheniramine 81
Promethazine 80
Cyproheptadine 57
Antidepressants
Amitriptyline 2585
Paroxetine 1352
Nortriptyline 760
Imipramine 667
Doxepin 505
Desipramine 173
Gastrointestinal antispasmodics
Anticholinergic combinations
Hyoscyamine 1066
Dicyclomine 516
Urinary antimuscarinics
Oxybutynin 983
Flavoxate 47
Antivertigo/antiemetics
Meclizine 924
Dimenhydrinate 69
Scopolamine 248
Skeletal Muscle Relaxants
Cyclobenzaprine 772
Orphenadrine 118
Antipsychotics
Perphenazine 53
Trifluoperazine 40
Thioridazine 38
Antiparkinson agents
Benztropine 36
Other
Disopyramide 139
aOnly medications with a frequency of 0.2 % or higher were listed
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studies have been limited in their ability to adjust
for physical function or physical activity, which are
potential confounders. Because of a prevalent user
design, these factors could also be influenced by
anticholinergic use (or in the causal pathway). In
addition, dizziness could be a confounder or a side
effect from anticholinergic use. To examine this
issue, we assessed a separate model (Model 3) that
included all variables from Model 2, with additional
adjustment for physical function, current physical ac-
tivity from walking, and dizziness.
In addition, we assessed the association between the
number of concurrent anticholinergic medications (0, 1
or ≥2), and duration of anticholinergic use at baseline
(<1 year, 1–3 years, >3 years) and the risk of recurrent
falls. We conducted trend tests for the number and dur-
ation of anticholinergic medication variables in order to
assess associations across categories. Given the hetero-
geneity in medication use patterns (i.e., chronic vs. inter-
mittent use as seen with many antihistamines) across
anticholinergic agents, we grouped anticholinergic sub-
classes into similar therapeutic groups (i.e., antihista-
mines, antidepressants/antipsychotics, gastrointestinal
antispasmodics, urinary antimuscarinics, antivertigo/an-
tiemetic, and miscellaneous) and assessed the association
between each group and recurrent falls controlling for
use of anticholinergics in other sub-classes. In addition
to the primary associations of interest, we developed an
interaction model to evaluate effect modification for re-
current falls based on history of a fall.
A sensitivity analysis was conducted to evaluate the
robustness of our study results. Because the clinical trial
arms of the WHI did not update many of the covariates
at year 3, we ran the primary analyses only on those par-
ticipants in the observational study sample, and updated
the covariates at the year 3 exposure. All analyses were
conducted using SAS statistical software, version 9.2
(SAS Institute Inc, Cary, North Carolina) with the GEN-
MOD procedure to run the GEE models.
Results
Among the baseline sample of 61,451 postmenopausal
women with complete data, the majority was white and
overweight or obese (Table 2). At baseline, 11.3 % older
women were using an anticholinergic medication
(Table 3). Of users at baseline, 25.6 % had reported using
the medication for less than 1 year, 36.2 % had used
from 1 to 3 years, and 38.2 % had used for more than
3 years. Use of multiple anticholinergic medications was
reported by 8.8 % of users. Compared to nonusers, indi-
viduals on anticholinergic medication were more likely
to be obese, have a history of falls, have several health
conditions (e.g., urinary incontinence, arthritis, low back
pain), have higher psychoactive medication use including
use certain medications (e.g., benzodiazepines, antide-
pressants), and have poorer physical function and poor/
fair self-reported health.
Using multivariable GEE models and controlling for
potential confounders, the adjusted odds ratio for any
anticholinergic medication use was 1.51 (95 % CI, 1.43–
1.60) for recurrent falls (Table 4). Adjustment for phys-
ical function, physical activity, and dizziness had negli-
gible impact on the odds ratio (Model 2 versus Model 3,
Table 4). Participants using ≥ 2 anticholinergic medica-
tions had a 100 % increase in likelihood of recurrent falls
(adjusted odds ratio [AOR] 2.00, 95 % CI 1.73–2.32). A
significant trend for increasing likelihood of recurrent
falls was detected with increasing duration of anticholin-
ergic medication use (trend test p-value <0.0001). More-
over, use of each anticholinergic sub-class was associated
with a statistically significant increase in likelihood of re-
current falls, with antidepressants/antipsychotics having
the largest adjusted odds ratio (AOR 1.81, 95 % CI,
1.66–1.97) among the sub-classes.
Our sensitivity analysis did not reveal a statistically sig-
nificant effect modification for recurrent falls based on
history of a fall (falls in prior year: none/<2, AOR 1.47,
95 % CI, 1.37–1.58; falls in prior year: ≥2, AOR 1.38,
95 % CI, 1.25–1.53; interaction p value, 0.32). In
addition, the sensitivity analysis including updated covar-
iates at year 3 revealed similar findings to the primary
analysis.
Discussion
We found that anticholinergic medication use was asso-
ciated with recurrent falls among older postmenopausal
women. The association with recurrent falls was even
greater among those using multiple anticholinergic med-
ications. In addition, we found a significant association
between longer duration of anticholinergic use and re-
current falls. Each of the anticholinergic sub-classes was
associated with recurrent falls; thus even anticholinergics
likely to be used intermittently (e.g. antihistamines) were
associated with recurrent falls. These findings were ro-
bust to sensitivity analysis.
A number of authoritative geriatric medicine sources
report that anticholinergic use may increase fall risk [10,
31], despite some inconsistencies in the data that sup-
port these recommendations. Thus, our study addresses
an important gap in the literature by evaluating the asso-
ciation between anticholinergic medication use and risk
for falls among a large sample of community-dwelling
women. The most comparable study to the current one
was conducted in 2948 community-dwelling older men
and women as part of the Health, Aging and Body Com-
position (ABC) study [13]. These authors also found an
increased risk of recurrent falls in individuals on anti-
cholinergic medication, but the results were not
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Table 2 Baseline Characteristics of Sample: Overall and by Anticholinergic Usea (n = 61,451)
Overall User of AC Non-use of AC
(n = 61,451) (n = 6940) (n = 54,511)
N % N % N %
Age group at screening
65–69 31,008 50.5 3427 49.4 27,581 50.6
70–74 21,491 35.0 2486 35.8 19,005 34.9
75+ 8952 14.6 1027 14.8 7925 14.5
Race/ethnicity
White 54,015 87.9 6264 90.3 47,751 87.6
Black 3572 5.8 314 4.5 3258 6.0
Hispanic 1241 2.0 160 2.3 1081 2.0
American Indian 200 0.3 34 0.5 166 0.3
Asian/Pacific Islander 1594 2.6 82 1.2 1512 2.8
Unknown 829 1.4 86 1.2 743 1.4
Number of falls in last 12 months (missing = 1658)
None 40,419 67.6 4194 61.8 36,225 68.3
1 12,200 20.4 1442 21.3 10,758 20.3
2 4946 8.3 734 10.8 4212 8.0
3 or more 2228 3.7 415 6.1 1813 3.4
Fair or poor self-reported health 5426 8.8 1049 15.1 4377 8.0
Smoking status (missing = 698)
Never 32,298 53.2 3486 51.0 28,812 53.4
Past 25,459 41.9 3017 44.1 22,442 41.6
Current 2996 4.9 337 4.9 2659 4.9
Minutes per week spent walking (missing = 137)
0 min 19,045 31.1 2494 36.0 16,551 30.4
>0–150 min 32,225 52.6 3529 51.0 28,696 52.8
>150 min 10,044 16.4 903 13.0 9141 16.8
Alcohol intake
Non drinker 7375 12.0 852 12.3 6523 12.0
Past drinker 11,657 19.0 1615 23.3 10,042 18.4
<7 drinks per week 34,646 56.4 3665 52.8 30,981 56.8
7+ drinks per week 7773 12.7 808 11.6 6965 12.8
BMI (kg/m2)
Underweight (<18.5) 619 1.0 58 0.8 561 1.0
Normal (18.5–24.9) 21,919 35.7 2184 31.5 19,735 36.2
Overweight (25.0–29.9) 22,341 36.4 2601 37.5 19,740 36.2
Obese (≥30.0) 16,572 27.0 2097 30.2 14,475 26.6
Rand Physical Function score >90 (missing = 731) 16,870 27.8 1191 17.4 15,679 29.1
Urinary incontinence 19,244 31.3 2754 39.7 16,490 30.3
History of Parkinson’s disease 228 0.4 64 0.9 164 0.3
Insomnia Rating Scale
0–3 15,317 24.9 1296 18.7 14,021 25.7
4–6 17,171 27.9 1698 24.5 15,473 28.4
7–10 16,493 26.8 2034 29.3 14,459 26.5
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statistically significant perhaps because of the smaller
sample size.
Conversely, a study by Berdot et al. on 6343
community-dwelling men and women aged ≥65 years
found that the risk of falls was not significantly increased
among individuals on anticholinergic medication in ad-
justed analysis [11]. However, when stratifying the ana-
lysis by type of anticholinergic use, Berdot et al. reported
a statistically significant increase in likelihood of falls for
regular but not occasional users compared to non users
[11]. Of note, the authors were not able to determine if
anticholinergic use had occurred before or after the fall
based on their operational definition of regular use.
Richardson et al. assessed the association between anti-
cholinergic use and self-reported injurious falls in
community-dwelling men and women aged ≥65 years in
Ireland and found a statistically significant association
between regular use and subsequent self-reported injuri-
ous falls in men, but not women [14]. In addition,
Nisthala et al. examined the impact of anticholinergic
and sedative medications (as measured by the Drug Bur-
den Index [DBI]) in people aged ≥65 years in New Zea-
land and found that exposure to DBI drugs was
independently associated with fall-related hospitaliza-
tions, primary care visits, and mortality [12]. However, it
Table 2 Baseline Characteristics of Sample: Overall and by Anticholinergic Usea (n = 61,451) (Continued)
≥11 12,470 20.3 1912 27.6 10,558 19.4
Depression (Burnham score >0.06) 5230 8.5 941 13.6 4289 7.9
Treated diabetes (oral or insulin) 2962 4.8 454 6.5 2508 4.6
Alzheimer Disease 35 0.1 2 0.03 33 0.1
Arthritis 34,728 56.5 4746 68.4 29,982 55.0
Anti-epileptic use 605 1.0 152 2.2 453 0.8
Benzodiazepine receptor agonist use 2563 4.2 860 12.4 1703 3.1
Antidepressant use 1710 2.8 409 5.9 1301 2.4
Antipsychotic use 54 0.1 27 0.4 27 0.1
Number of psychoactive meds
0 57,378 93.4 5723 82.5 51,655 94.8
1 3666 6.0 1072 15.5 2594 4.8
2+ 407 0.7 145 2.1 262 0.5
Dizziness (moderate/severe) (missing = 156) 1829 3.0 412 6.0 1417 2.6
Low back pain (moderate/severe) 12,719 20.7 2160 31.1 10,559 19.4
Vision problem uncorrected (moderate/severe) 3560 5.8 550 7.9 3010 5.5
WHI Participation
Hormone therapy trial 10,986 17.9 1180 17.0 9806 18.0
Diet modification trial 16,497 26.9 1754 25.3 14,743 27.1
Calcium vitamin D trial 12,706 20.7 1272 18.3 11,434 21.0
Observational study 36,723 59.8 4288 61.8 32,435 59.5
Abbreviation: AC anticholinergic
aMissing value is 0 unless otherwise specified
Table 3 Descriptives of Anticholinergic Medication Use
Prevalence at Baseline and Year 3
Baseline Year 3
N % N %
Any Use 6940 100.00 6985 100.00
Number of Agents
1 6332 91.24 6333 90.67
2+ 608 8.76 652 9.33
Duration
<1 year 1775 25.58 1786 25.57
1–3 years 2514 36.22 3306 47.33
>3 years 2651 38.20 1893 27.10
Specific Anticholinergic Class
Antihistamines 3136 45.19 2355 33.72
Antidepressants/Antipsychotics 2252 32.45 2381 34.09
Gastrointestinal antispasmodics 670 9.65 499 7.14
Urinary antimuscarinics 582 8.39 1653 23.66
Antivertigo/antiemetics 521 7.51 429 6.14
Miscellaneousa 344 4.96 301 4.31
aMiscellaneous: antiparkinson agents and disopyramide
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was not possible to disentangle the independent effect of
anticholinergic use from the overall DBI drug exposure.
While the literature regarding anticholinergic use and
falls in older adults remains somewhat mixed, mounting
evidence – including the results from our current study
– suggests a significant association.
Given that many anticholinergic medications are over-
the-counter, they may be used only intermittently (e.g.,
antihistamines). Medications with anticholinergic prop-
erties may increase falls risk by several mechanisms, in-
cluding blurred vision, sedation, and cognitive
impairment, therefore it is plausible that even intermit-
tent use could increase risk via these adverse events [5,
6]. We explored this issue by performing our sub-class
analysis where we found that even antihistamines were
significantly associated with falls. It is also important to
note that since antihistamines were the most commonly
used therapeutic class of anticholinergics, studies relying
on claims data to measure medication exposure would
not capture antihistamines purchased over-the-counter
and used intermittently. Future research would be
strengthened by examining the association between pat-
terns of anticholinergic use (including sporadic use) and
falls.
Strengths of this study include the large sample of di-
verse women and extensive covariate information. In
particular, we were able to adjust for important potential
confounders not available in most administrative claims
datasets, including physical function, physical activity,
and dizziness. However, there are several limitations that
warrant discussion. First, multiple scales exist for meas-
uring anticholinergic exposure, with no true gold stand-
ard [32]. A study by Naples et al. found only low to
moderate concordance among five commonly used
Table 4 Adjusted Odds Ratios Relating Anticholinergic Use to Incident Recurrent Falls over the next 12 monthsa
Model 1 Model 2 Model 3
Number With
falls
OR (95 % CI) Number With
falls
OR (95 % CI) Number With
falls
OR (95 % CI)
Any Anticholinergic use
No use 7883 1.0 7883 1.0 7743 1.0
Any use 1938 1.86 (1.76,
1.97)
1938 1.53 (1.45,
1.62)
1903 1.51 (1.43,
1.60)
Number of Agents*
No use 7883 1.0 7883 1.0 7743 1.0
1 1688 1.78 (1.67,
1.88)
1688 1.48 (1.40,
1.57)
1657 1.47 (1.38,
1.56)
2+ 250 2.84 (2.45,
3.28)
250 2.04 (1.76,
2.36)
246 2.00 (1.73,
2.32)
Duration*
No use 7883 1.0 7883 1.0 7743 1.0
<1 year 495 1.82 (1.64,
2.01)
495 1.52 (1.37,
1.68)
485 1.50 (1.36,
1.66)
1–3 years 760 1.73 (1.59,
1.88)
760 1.42 (1.31,
1.55)
745 1.41 (1.29,
1.53)
>3 years 683 2.10 (1.92,
2.29)
683 1.70 (1.55,
1.86)
673 1.68 (1.53,
1.84)
Specific Anticholinergic Classb
Antihistamine/Antiemetic/Antivertigo 742 1.39 (1.28,
1.51)
742 1.22 (1.12,
1.32)
734 1.21 (1.11,
1.32)
Antidepressant/Antipsychotic 811 2.26 (2.07,
2.46)
811 1.83 (1.67,
1.99)
796 1.81 (1.66,
1.97)
Gastrointestinal/Urinary Antimuscarinics/
Miscellaneous
607 1.81 (1.64,
1.99)
607 1.49 (1.35,
1.64)
591 1.47 (1.33,
1.62)
Abbreviations: CI confidence intervals, OR odds ratio
*Trend test p-values all <0.0001
aOR and CI are estimated from GEE models using an unstructured correlation matrix, including baseline and year 3 medication exposure information, and
recurrent falls in the following year. All models are adjusted by age using 5-year age intervals, and study component (clinical trial vs. observational study). Model
1 adjusted for linear age, diet modification and CaD trial randomization arms. Model 2 was further adjusted for race/ethnicity, body mass index, poor vision, arth-
ritis, treated diabetes, low back pain, Alzheimer’s Disease diagnosis and/or use of medication, indications for use (Parkinson’s disease, urinary incontinence, depres-
sion, insomnia scale), self-reported health, alcohol intake, use of antiepileptics, and number of psychoactive medications. Model 3 was further adjusted for
physical function, dizziness, current physical activity from walking. All adjustment variables are from baseline
bOdds ratios for type of anticholinergic medication are adjusted for simultaneous use of a different type
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anticholinergic scales [33]. To address this potential
limitation, we included medications with moderate and
strong anticholinergic activity and avoided medications
with more questionable anticholinergic activity, poten-
tially leading to a lower prevalence of anticholinergic
medication use and thus a conservative estimate of the
association between anticholinergic use and recurrent
falls. Furthermore, our list is very similar to the medica-
tions identified as highly anticholinergic on the 2012 up-
dated Beers criteria [10]. Medication information was
only collected at baseline and year 3. As a result, anti-
cholinergics users were likely to be those who tolerated
the early adverse effects, and women experiencing ad-
verse events may have discontinued the anticholinergics
prior to their capture in our periodic assessment of
medication use. This would be expected to bias our re-
sults towards the null and, therefore, our results are
likely conservative. Finally, we did our best to adjust for
baseline differences, but like all observational studies, re-
sidual or unmeasured confounding could explain our
findings.
Conclusions
In conclusion, use of medications with strong or moder-
ate anticholinergic effects in older women is associated
with a slightly higher risk of recurrent falls, especially in
those taking multiple agents or for 3 or more years.
Anticholinergic medications have several potential ad-
verse events (e.g., memory impairment, constipation,
urinary retention), yet they continue to be widely used.
Health care providers are encouraged to use anticholin-
ergic medications judiciously and resort to alternative
therapies when available. Since many medications with
anticholinergic effects are available without a prescrip-
tion, an effort to increase awareness among older adults
of the potential for increased falling risk is an important
public health priority.
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